Table 2.
Adverse event experienced in the clinical development of full length PTH
| Very common (>1/10) n (%) | Common (>1/100 and <1/10) n (%) | Uncommon (>1/1000 and <1/100) n (%) | |
|---|---|---|---|
| Renal and urinary disorders | |||
| Hypercalcuria | 39.3 | ||
| Urine calcium/creatinine ratio increased | 2.9 | ||
| Urine calcium increased | 2.2 | ||
| Metabolism and nutrition disorders | |||
| Hypercalcemia | 25.3 | ||
| Blood calcium increased | 3.1 | ||
| Blood alkaline phosphatase increased | 0.8 | ||
| Anorexia | 0.6 | ||
| Blood uric acid increased | 0.6 | ||
| Gastrointestinal disorders | |||
| Nausea | 13.5 | ||
| Vomiting | 2.5 | ||
| Constipation | 1.8 | ||
| Dyspepsia | 1.3 | ||
| Diarrhea | 1.0 | ||
| Abdominal pain | 0.8 | ||
| Nervous system disorders | |||
| Headache | 9.3 | ||
| Dizziness | 3.9 | ||
| Dysgeusia | 0.8 | ||
| Parosmia | 0.7 | ||
| General disorders and administration site conditions | |||
| Injection site erythema | 2.6 | ||
| Fatigue | 1.8 | ||
| Asthenia | 1.2 | ||
| Injection site irritation | 0.9 | ||
| Musculoskeletal, connective tissue, and bone disorders | |||
| Muscle cramp | 1.1 | ||
| Pain in extremity | 1.1 | ||
| Back pain | 1.0 | ||
| Cardiac disorders | |||
| Palpitations | 1.0 | ||
| Infections and infestations | |||
| Influenza | 0.5 | ||
Abbreviations: PTH, parathyroid hormone.